Exelixis (EXEL) Set to Release Earnings on Thursday

Key Points

• Exelixis is scheduled to report Q3 2026 earnings after market close on October 29. Analysts expect earnings of $0.879 per share and revenue of approximately $646.5 million.
• The company’s latest quarter beat EPS estimates, reporting $0.91 versus the $0.85 consensus, while revenue increased 10.6% year over year to $628.7 million but fell short of expectations.
• EXEL shares opened at $64.58, near their 52-week high of $64.78, despite analysts’ consensus “Hold” rating and average price target of $51.50.

Exelixis (NASDAQ:EXEL - Get Free Report) is expected to be announcing its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect Exelixis to post earnings of $0.8790 per share and revenue of $646.52 million for the quarter. Investors may visit the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, October 29, 2026 at 5:00 PM ET.

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $0.91 EPS for the quarter, beating analysts' consensus estimates of $0.85 by $0.06. Exelixis had a return on equity of 42.17% and a net margin of 35.33%. The company had revenue of $628.69 million during the quarter, compared to the consensus estimate of $636.40 million. During the same quarter in the prior year, the company earned $0.75 earnings per share. The firm's revenue for the quarter was up 10.6% on a year-over-year basis. On average, analysts expect Exelixis to post $3.19 EPS for the current fiscal year and $3.71 EPS for the next fiscal year.

Exelixis Stock Up 0.3%

Shares of EXEL stock opened at $64.58 on Thursday. The stock has a fifty day moving average of $57.63 and a 200 day moving average of $53.38. Exelixis has a 52 week low of $35.44 and a 52 week high of $64.78. The firm has a market capitalization of $16.00 billion, a price-to-earnings ratio of 20.31, a PEG ratio of 1.81 and a beta of 0.47.

Insider Buying and Selling at Exelixis

In related news, Director Mary Beckerle sold 9,812 shares of the company's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $53.66, for a total value of $526,511.92. Following the sale, the director directly owned 16,079 shares of the company's stock, valued at $862,799.14. This represents a 37.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.60% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Morgan Stanley upped their price objective on shares of Exelixis from $50.00 to $53.00 and gave the stock an "equal weight" rating in a report on Thursday, July 23rd. Stifel Nicolaus lifted their target price on shares of Exelixis from $47.00 to $51.00 and gave the company a "hold" rating in a research note on Thursday, August 6th. Royal Bank Of Canada lifted their target price on shares of Exelixis from $45.00 to $51.00 and gave the company a "sector perform" rating in a research note on Friday, October 9th. Citigroup reiterated a "market outperform" rating on shares of Exelixis in a research report on Monday. Finally, Zacks Research upgraded shares of Exelixis from a "strong sell" rating to a "hold" rating in a research report on Tuesday, September 1st. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $51.50.

About Exelixis

Exelixis, Inc is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for cancer and other serious diseases. The company's research programs center primarily on targeted therapies, including treatments designed to inhibit signaling pathways involved in tumor growth and progression.

Exelixis' lead product is CABOMETYX (cabozantinib), an oral medicine approved in the United States for certain patients with renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.